Estamos no ar no ! Saiba mais
118,28 USD
-3,01
2,48%
No fechamento Atualizado 16 de out. 16:00 EDT
Pré-mercado
Após o fechamento do mercado
118,52
+0,24
0,2%
1 dia
-2,48%
5 dias
-0,35%
1 mês
11,33%
3 meses
50,68%
6 meses
96,77%
No acumulado do ano
47,89%
1 ano
137,65%
5 anos
76,35%
10 anos
243,14%
 

Sobre: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.

Funcionários: 3.009

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 59,3%
Neutro 29,6%
Negativo 11,1%
Positivo
Zacks Investment Research
há 14 horas
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
Negativo
Zacks Investment Research
ontem
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's MedSurg growth and NexSys PCS adoption support its prospects, but competitive pressures and unfavorable currency movements pose risks.
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Positivo
Zacks Investment Research
há 3 dias
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Positivo
Zacks Investment Research
há 7 dias
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Positivo
Proactive Investors
há 8 dias
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices
Haemonetics (NYSE:HAE) shares jumped over 13% to $115.20 on Thursday after CSL set out a timetable for moving its US plasma collection centers onto the company's devices. CSL Limited (ASX:CSL), the Australian biotechnology company, expects to finish rolling out Haemonetics' NexSys PCS devices with Persona PLUS technology and related disposables by the end of 2027.
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices
Positivo
Barrons
há 8 dias
Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue
CSL Plasma plans to use Haemonetics' plasma collection equipment across all existing U.S. centers, expanding the scope of an earlier supply agreement.
Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue
Positivo
Zacks Investment Research
há 11 dias
PAHC vs. HAE: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
PAHC vs. HAE: Which Stock Is the Better Value Option?
Neutro
PRNewsWire
há 16 dias
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026.
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
Positivo
Zacks Investment Research
há 22 dias
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?
Positivo
Zacks Investment Research
há 28 dias
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
Gráficos de preços implementados com Lightweight Charts™